USFDA concludes audit at Cohance Lifesciences Jaggaiahpet facility
USFDA concludes audit at Cohance Lifesciences Jaggaiahpet facility Written by Ruchika Sharma Published On 2025-09-13T12:37:31+05:30 | Updated On 13 Sept 2025 12:37 PM ISTHyderabad: Cohance Lifesciences has announced that the United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at our API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh. The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations. "We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets," the company stated in a BSE filing.Read also: Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ BioCohance Lifesciences is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules.Read also: Advent International to purchase significant stake in Suven Pharma, plans merger with Cohance Lifesciencescohance lifesciencesUSFDAUSFDA inspectionRuchika SharmaRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751Show Full ArticleNext Story